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Abstract
While response rates to BRAF inhibitiors (BRAFi) are high, disease progression emerges quickly. One strategy to delay the
onset of resistance is to target anti-apoptotic proteins such as BCL-2, known to be associated with a poor prognosis. We
analyzed BCL-2 family member expression levels of 34 samples from 17 patients collected before and 10 to 14 days after
treatment initiation with either vemurafenib or dabrafenib/trametinib combination. The observed changes in mRNA and
protein levels with BRAFi treatment led us to hypothesize that combining BRAFi with a BCL-2 inhibitor (the BH3-mimetic
navitoclax) would improve outcome. We tested this hypothesis in cell lines and in mice. Pretreatment mRNA levels of BCL-2
negatively correlated with maximal tumor regression. Early increases in mRNA levels were seen in BIM, BCL-XL, BID and BCL2-
W, as were decreases in MCL-1 and BCL2A. No significant changes were observed with BCL-2. Using reverse phase protein
array (RPPA), significant increases in protein levels were found in BIM and BID. No changes in mRNA or protein correlated
with response. Concurrent BRAF (PLX4720) and BCL2 (navitoclax) inhibition synergistically reduced viability in BRAF mutant
cell lines and correlated with down-modulation of MCL-1 and BIM induction after PLX4720 treatment. In xenograft models,
navitoclax enhanced the efficacy of PLX4720. The combination of a selective BRAF inhibitor with a BH3-mimetic promises to
be an important therapeutic strategy capable of enhancing the clinical efficacy of BRAF inhibition in many patients that
might otherwise succumb quickly to de novo resistance.
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Introduction
Vemurafenib and dabrafenib are selective BRAF inhibitors that
improve overall survival when compared with dacarbazine in
patients with advanced, BRAF-mutant melanoma [1,2]. While
these results have changed the standard of care for these patients,
there remain critical limitations to the activity of these agents.
Specifically, clinical resistance develops in most patients within one
year, the median progression free survival (PFS) is 5–6 months,
and durable remissions are uncommon [1–5]. Acquired resistance
to BRAFi therapy is mediated by multiple mechanisms that lead to
reactivation of the mitogen activated protein kinase (MAPK)
pathway or upregulation of other pro-survival signaling pathways
[e.g. phosphoinositide-3-kinase (PI3K) pathway] [6–17] While less
is known about de novo resistance to therapy, stromal production of
HGF and PTEN deficiency each have been shown to be associated
with poorer outcomes through unopposed PI3K pathway activity.
Another recently described mechanism of de novo resistance to
BRAFi therapy is dysregulation of the cell cycle, either through
overexpression of CCND1 (cyclin D1) or loss of the cyclin
dependent kinase inhibitor, CCDNK2A (p16
INK4A). Finally, our
group has recently described that high BCL2A1 (an anti-apoptotic
BCL-2 family member) expression is associated with resistance to
BRAFi-induced apoptosis in vitro and with a lower response rate in
patients treated with a BRAFi [17,18].
BCL-2 family proteins are major regulators of the apoptotic
threshold and are deregulated in many cancer types [19]. The
anti-apoptotic members of the BCL-2 family, known as multi-
domain anti-apoptotic proteins, include: BCL-2, BCL2-L1 (BCL-
XL), BCL2-L2 (BCL-W), MCL-1, and BCL-2A1 (BFL-1). In
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Umelanoma, altered BCL-2, BCL-XL, and MCL-1 expression are
associated with malignant transformation of melanocytic cells and
progression to melanoma [20]. In addition, increased expression of
BCL-XL is associated with a poor prognosis in patients with
melanoma and elevated BCL-2 and BCL-XL are associated with a
poor response to chemotherapy [21–23].
Over-expression of the multi-domain anti-apoptotic proteins
contributes to apoptosis resistance in multiple types of cancer
including melanoma. However, there are a number of pro-
apoptotic BCL-2 family members that facilitate apoptosis through
inhibiting the anti-apoptotic family members and activating the
mitochondrial cell death pathway. The two multi-domain pro-
apoptotic proteins, BAK and BAX, reside in the outer mitochon-
drial membrane and, when activated, lead to the depolarization of
the mitochondria and the subsequent release of cytochrome C, as
well as other mediators of apoptosis. Activation of BAK and BAX
is mediated through interactions with a third class of BCL-2 family
members known as the BCL-2 Homology 3 domain (BH3) only
proteins. The activator BH3-only proteins, BID and BIM, initiate
apoptosis by binding directly to BAK and BAX. Other BH3-only
proteins, however, such as BAD, BMF, BIK, HRK, NOXA and
PUMA, are able to bind and regulate (or be regulated by) the anti-
apoptotic BCL-2 proteins [24].
One potential way to enhance the effectiveness of BRAF-
directed therapy is to focus on mechanisms that lower the
threshold for apoptotic induction by MAPK pathway inhibitors.
Mutant BRAF modulates proapoptotic BCL-2 family members,
including the inactivation of BAD and downregulation of BIM,
serving to protect the cell from apoptosis [25,26]. In preclinical
models, inhibition of BRAF or MEK, either through small
interfering RNA (siRNA) or small molecule inhibitors, initiates
both growth arrest and apoptosis. This is at least in part caused by
upregulation of BIM and its associated suppression of two anti-
apoptotic BCL-2 family members, BCL-2 and MCL-1 [27,28]. In
patients, single agent BRAFi therapy is associated with inconsistent
induction of apoptosis that is not associated with clinical outcome
[29,30]. We hypothesized that BRAF inhibitor therapy would
modulate both pro- and anti-apoptotic BCL-2 family members
and sought to investigate the effects of BRAF-directed therapy on
the RNA and protein expression of BCL-2 family members, by
comparing pre- and on-treatment biopsies of patients with BRAF
mutant melanoma treated with either single-agent vemurafenib or
the combination of dabrafenib and trametinib. Furthermore, we
evaluated the cytotoxic effects of combining a BH3-mimetic,
navitoclax, with a BRAF inhibitor in vitro and in vivo in melanoma
cell lines.
Materials and Methods
Patient samples
Patients with metastatic melanoma containing BRAF
V600E
mutation (confirmed by genotyping) were enrolled on clinical
trials for treatment with a BRAF inhibitor (vemurafenib) or
combined BRAF + MEK inhibitor (dabrafenib + trametinib;
Table S1). All samples were obtained from participants who signed
an informed consent form. The current IRB approval letter has
been attached. This protocol was reviewed and approved by the
Dana-Farber Cancer Institute (DFCI) IRB, in accordance with the
applicable Federal regulations set forth at 45 CFR Part 46, and 21
CFR Parts 50 and 56. All relevant clinical trials are registered at
ClinicalTrials.gov. ClinicalTrials.gov numbers are as follows:
NCT01006980, NCT01107418, NCT01264380, NCT01248936,
NCT00949702, and NCT01072175. Tumor biopsies were con-
ducted pretreatment (day 0) and at 10 to 14 days on treatment.
Formalin-fixed tissue was analyzed to confirm that viable tumor
was present via hematoxylin and eosin (H&E) staining. Additional
tissue was snap-frozen and stored in liquid nitrogen or was
immediately processed for purification of RNA.
Clinical Response
RECIST criteria were used to classify response, and are defined
as follows: Complete Response (CR): Disappearance of all target
lesions. Partial Response (PR): At least a 30% decrease in the sum
of the longest diameter (LD) of target lesions, taking as reference
the baseline sum LD. Stable Disease (SD): Neither sufficient
shrinkage to qualify for PR nor sufficient increase to qualify for
PD, taking as reference the smallest sum LD since the treatment
started. Progressive Disease (PD): At least a 20% increase in the
sum of the LD of target lesions, taking as reference the smallest
sum LD recorded since the treatment started or the appearance of
one or more new lesions.
Purification of total RNA
Patient samples were homogenized and disrupted using a
mortar and pestle followed by use of a QIAshredder. A QIAcube
was used to harvest RNA from both patient biopsies and cell
lysates using the RNeasy Mini Protocol (Qiagen).
Quantitative PCR
Total RNA (250 ng) was used as template, and Superscript
VILO cDNA Synthesis Kit (Invitrogen) was used to generate
cDNA. Quantitative real-time PCR was carried out on an Applied
Biosystems 7300 machine. Primers for PCR are described in Table
S2.
RPPA
Protein lysates were isolated from SNAP frozen patient tumors
and processed for reverse phase protein array (Methods RPPA S1).
Cell lines and reagents
Malignant melanoma cell lines were obtained from the
American Type Culture Collection (ATCC) and kindly donated
by the Department of Dermatology (Hensin Tsao lab) from the
Massachusetts General Hospital (MGH) between 2011 and 2012.
Cells were authenticated following ATCC recommendations
(ATCC Tech bulletin #8), and used within one week after
authentication. Cells were passaged for less than six months after
received. Cell morphology and growth analysis were performed
posterior to resuscitation. All cell lines were maintained and all
experiments were performed in DMEM (Sigma, D 6429)
supplemented with 10% (v/v) FBS (Gibco) and 1% (v/v)
penicillin-streptomycin (Life Technologies). For in vitro studies,
BRAF inhibitor, PLX4720 (Selleck Chem), and BCL-2/BCL-XL
inhibitor, ABT-263 (Selleck Chem) were used.
Cell Proliferation Assays
Cellular proliferation was evaluated by MTT assay (3-(4,5-
dimethylthiazole- 2-yl)-2,5-diphenyl- 2H-tetrazolium bromide;
Sigma-Aldrich) following manufacturer instructions. Cells were
plated in 96-well plates at 1,000 to 10,000 cells per well in 100 mL
of media and treated 24 hours after plating. MTT signal was read
at 72 hours after treatment. The IC50 and Combination Index
(CI) by Chou-Talalay were determined from the regression plot
logarithm of the concentration versus effect using Calcusyn
Software (Biosoft) v1.1. In addition, conservative isobolograms
were used to show synergism and/or antagonism.
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Immunoblotting was performed using Cell Signaling general
protocols, antibodies: Cell Signaling; MCL1 Rabbit Ab 4572S,
BIM (C34C5) Rabbit Ab, #2933S, GAPDH (14C10) Rabbit Ab
#2118, Millipore; b-Tubulin (KMX-1) Mouse Ab #3408.
Annexin:PI apoptosis assay by flow cytometry
Annexin V staining was performed using the Annexin-V-FITC
apoptosis detection kit (BD Pharmingen) following manufacturer’s
protocol in package insert. 5610
5 cells were seeded into 6 well
plates in DMEM and 10% FBS (GIBCO) and Pen-strep (Life
Technologies) 24 hours prior to treatment. Cells were treated for
24 hours with the specified drug concentration. After harvesting
by trypsinization, cells were washed twice with cold phosphate-
buffered saline. 3610
4 cells were resuspended in 100 mlo f1 X
Binding Buffer and stained with 5 ml of propidium iodide (PI) and
5 ml of annexin-V solution for 15 min at RT in the dark. After
incubation, 400 ml of 1X Binding Buffer was added to each tube
and the samples were examined by flow cytometry (FACS calibur).
Controls (unstained cells and single-stained cells with Annexin V
or PI) enabled the compensation and definition of quadrants for
posterior analysis using WinMDI 2.9.
Xenograft Model
Athymic nude mice Nu/Nu (Crl:NU-Foxn1nu), 4 weeks of age
were purchased from Charles River Laboratories and Taconic
Farms. All animal work was conducted according to relevant
national and international guidelines under a Beth Israel
Deaconess Medical Center Animal Care and Use Committee
approved document. Cell lines A375 and A2058 (BRAF V600E
mutant) were obtained from the American Type Culture
Collection (ATCC) and authenticated by isoenzymology. The
Cytochrome C subunit I (COI) PCR assay was performed for
confirmation of species and cell line had identity was confirmed by
STR analyses. Cells were injected SC at 5610
6 cells per mouse.
Mice were randomized once an average of ,300 mm
3 tumor
volume was reached (For A375 and A2058, average time was 7 to
9 days). After randomization, treatment was started. Mice were
sacrificed following the guidelines by the Institutional Animal Care
and Use Committee (IACUC) for MGH. Tumor volumes were
determined using [D6(d
2)]/2, in which D represents the largest
diameter of the tumor, and d represents the largest perpendicular
volume to D. Tumor volumes were normalized individually to
their initial volume (Volume at treatment day 1) (Relative tumor
Volume =Vx/V0; were Vx corresponds to the volume for the
specific animal at a particular day and V0 corresponds to the initial
volume for the given animal. BRAF inhibitor, PLX4720 (Selleck),
was diluted in DMSO to a 20 mg/mL stock. Stock was diluted in
1% Methyl-cellulose (10 mg Methyl-cellulose/mL of H2O) for
daily oral gavage at 100 mg/kg/day. Navitoclax (ABT-263) was
dissolved in 60% Phosal 50 PG (American Lecithin), 30% polyethylene
glycol 400, 10% EtOH vehicle and administered PO at 100 mg/
kg/day. Statistical analysis consisted of Mann-Whitney Rank Sum
Test, two-way ANOVA, and post hoc Bonferroni using GraphPad
Prism, version 4.3.
IHC in Xenografts
Tumors were fixed in 10% neutral buffered formalin, embed-
ded in paraffin, and sectioned at five microns 3 days after
treatment commenced. Deparaffinized and rehydrated sections
were subjected to epitope retrieval in 10 mM Tris-EDTA buffer
pH 9.0 and blocking in 3% BSA in TBST (Tris pH 7.6, 0.05%
Tween-20). BIM (Cell Signaling C34C5) Rabbit Ab (1:100 in 3%
BSA in TBST) was applied for 1 hr at RT. After peroxidase block
Figure 1. Pre treatment BCL-2 expression in tumors of patients with metastatic melanoma negatively correlates with response to
BRAF inhibition. (A) Linear regression between duration of patient response to BRAF inhibition and BCL-2 expression levels relative to endogenous
gene bActin prior to treatment (n=17, R=20.56, p=0.0097, dotted red lines indicate 95% confidence intervals). (B) Patients who progress in less
than 5.3 months have higher levels of BCL2 mRNA expression relative to bActin pre-treatment than patients with an above average duration of
response to BRAF inhibition (P#0.05).
doi:10.1371/journal.pone.0101286.g001
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melanoma. mRNA levels of BIM, BCL2-XL, BCL2-W, BID increased in patients with metastatic melanoma undergoing treatment with a selective
inhibitor of BRAF
V600E while mRNA levels of MCL-1 decreased; BCL2 levels did not change significantly across patients. (A) mRNA expression levels of
each gene from pre and on treatment biopsies from each patient were quantified by real-time PCR and are plotted as log fold change. Each number
along the x-axis indicates an individual patient identifier, the y-axis indicates the mRNA level changes of BCL-2 family members for each patient. (B)
Changes in mRNA expression levels across patients 10–14 days after initiation of BRAFi are plotted on a log scale as fold change from pre-treatment
levels using box and whisker plots (*=P#0.05).
doi:10.1371/journal.pone.0101286.g002
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EnVision, K4003, RTU) was applied for 30 minutes. Slides were
developed with DAB+ (Dako K3468) and counterstained with
hematoxylin (Vector H-3401) prior to dehydration and mounting.
Apoptosis in Xenografts
Tumors were fixed in 10% neutral buffered formalin, embed-
ded in paraffin, and sectioned at five microns 3 days after
treatment commenced. Deparaffinized and rehydrated sections
Figure 3. Protein expression levels of BCL2 family members in patients undergoing treatment with a BRAF inhibitor. RPPA analysis of
tumors from patients with metastatic melanoma shows a significant increase of BID and BIM on BRAFi. (A) Protein expression levels of each gene
from pre and on treatment biopsies for each patient are shown as log fold change on treatment. (B) Changes in protein expression levels across
patients 10–14 days after initiation of BRAFi are plotted on a log scale as fold change from pre-treatment levels using box and whisker plots (*=P#
0.05).
doi:10.1371/journal.pone.0101286.g003
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protocol (Catalog #4810-30-K) and visualized by light microsco-
py.
Statistical Analysis
If not indicated otherwise, data represent results for assays
performed in triplicate, with error bars to represent standard
errors from the mean. All box plots and linear regressions
performed using the R statistical package.
Results
BCL-2 expression correlates with tumor response after
BRAF inhibition in melanoma
We evaluated pretreatment mRNA expression of BCL-2 family
members, BCL-2, MCL-1, BCL-XL, BCL-W, BIM, and BID in
tumors of patients with metastatic melanoma. Pre-treatment
expression levels of BCL-2 in melanoma patient samples inversely
correlated with tumor response after BRAF inhibition (Figures 1A
and 1B), while pretreatment levels of the other assayed BCL-2
family members had no correlation with outcome (Figure S1).
Change in mRNA and protein expression of BCL-2 family
members and markers of apoptosis in pre- and post-
BRAF inhibition in tumor samples
We tested the mRNA and protein expression of BCL-2 family
members in tumor samples from patients with metastatic
melanoma 10–14 days into treatment with a BRAF inhibitor.
We found no significant change in BCL-2 mRNA expression upon
treatment. However, we found a statistically significant increase in
expression of BIM, BCL-XL, BCL-W, and BID mRNA in samples
from patients upon BRAF inhibition as well as a significant
reduction in MCL-1 (Figures 2A and 2B) [31]. There was no
correlation between clinical benefit and the magnitude of change
in mRNA levels of any of these genes after BRAF inhibition.
Protein expression of the BCL-2 family members MCL-1, BCL-2,
BCL-XL and BCL-W were not significantly changed while BIM
and BID levels increased in the setting of BRAFi therapy
(Figures 3A and 3B). Similarly, there is no significant increase of
CASP7 in the setting of BRAFi therapy, though there is significant
variability of effects on CASP7 in individual patient samples.
In vitro mutant BRAF inhibition modulates BIM and MCL-
1 expression similarly to clinical BRAF inhibition in
patients with BRAF-mutant melanoma
We assayed a panel of BRAF
V600E mutant human melanoma
cell lines for the same group of BCL2 family members and found
them to recapitulate the responses found in patients. BRAF
inhibition of the MAPK pathway resulted in significant increases
in mRNA levels of BIM and BCL2-W (p,0.05) (Figures 4A and
4B), consistent with clinical samples. Increased levels of BID and
BCL2-XL (p,0.08) and decreased mRNA levels of MCL-1 (p,
0.08) were also observed in vitro after treatment with BRAF
inhibition in most but not all cell lines. Also consistent with patient
samples, BCL2 levels did not change across cell lines (Figures 4A
and 4B). Using the Broad-Novartis Cancer Cell Line Encyclopedia
we did not see a correlation, however, between BCL2 levels pre-
treatment and sensitivity to BRAF inhibition as measured by IC50
across 22 BRAF mutant melanoma cell lines. Protein levels of BIM
and MCL-1 were probed across our panel of cell lines (Figure 5D
and Figure S2B) at 2, 6 and 24 hours after treatment and were
found to be consistent with the RNA results.
Concomitant inhibition of both BCL-2 and mutant BRAF
synergistically suppress cell growth and augment
apoptosis
Having observed that higher pre-treatment levels of BCL2 were
a predictor of poor response to BRAFi and that the anti-apoptotic
Figure 4. Expression levels of BCL2 family members in a panel of BRAF mutant cell lines undergoing BRAF inhibition. (A) mRNA
expression levels of various BCL2 family members were quantified by real-time PCR changes and are plotted as log fold difference from vector control
(DMSO). (B) Across our panel of cell lines, BCL2-W and BIM increased significantly from control in the context of BRAF inhibition. PLX4720 (1 mM) was
used as BRAF inhibitor.
doi:10.1371/journal.pone.0101286.g004
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combining BRAF inhibition with BCL2/BCL2-XL inhibition
would mitigate resistance to BRAFi. We evaluated cell growth in
melanoma cell lines after BCL-2/BCL-XL inhibition with ABT-
263 and BRAF inhibition with PLX4720 using MTT assays. Both
inhibitors reduced cell viability in a dose related manner
(Figures 5A and B). The effect of the combination was greatest
between 48 and 72 hours of treatment. Using Chou-Talaly
method for combination studies, we found that the combination
of both inhibitors results in a synergistic reduction of cell growth in
the tested cell lines in a broad range of combination ratios (i.e. 1:1;
1:2 and 1:10) as evidenced by combination index studies
(Figures 5A and 5B) [32]. We directly assessed apoptosis following
BH3 mimetic and BRAF treatment therapy using Annexin:PI by
fluorescence activated cell sorting (FACS). As reported by others,
the effects of BRAF inhibition on apoptosis is dose- and cell line
dependent [33,34]. As expected, despite increased levels of BIM,
the resulting increase in apoptosis seems to be modest (Figure 5C).
As monotherapy, the effects of ABT-263 on apoptosis were
comparable to that observed with BRAF inhibition, suggesting the
need for an additional stimuli to induce apoptosis. The combina-
tion of both inhibitors results in an increase of apoptosis and cell
death in a dose- and cell line dependent manner (Figure 5C and
Figure S2A).
BH-3 mimetic treatment, BRAF inhibition, and their
combination reduce tumor growth in BRAF V600E
mutant xenografts
We evaluated the effects of navitoclax and PLX4720 or their
combination in vivo. Oral administration of compounds ABT-263
or PLX4720 were used to produce BCL-2 and BRAF inhibition in
mice. We used 100 mg/kg/d PO daily as our treatment dose and
Figure 5. The effect of BRAF inhibition, BH3-mimetics or their combination on cell proliferation, apoptosis and protein expression
levels of BCL2 family members in BRAF
V600E melanoma cell lines. (A) MTT assay demonstrating the effect of BCL-2 inhibition, BRAF
inhibition, and their combination, on cell proliferation with their respective combination index (CI) value. (B) Corresponding isobolograms. (C)
Fluorescence activated cell-sorting (FACS) for Annexin after indicated drug treatment in a BRAF
V600 cell line, A375. Drug combinations used at a 1:1
ratio. (D) Western blotting of BIM and MCL1 in a BRAF
V600 cell line, A375 after 2, 6 and 24 hours treatment with a BRAFi, ABT and the combination of
both BRAFi and ABT.
doi:10.1371/journal.pone.0101286.g005
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suppressed tumor growth in A375 and A2058 xenograft mouse
models (Figures 6A and 6B). Both inhibitors were well tolerated
with no overt toxic effects or weight loss. The combination of
ABT-263 and PLX4720 was well tolerated and resulted in
enhanced tumor growth suppression in both sensitive and
resistance models. BIM levels were increased in these tumors
and TUNEL staining confirmed the presence of at least some cells
undergoing apoptosis (Figure S3). Greater tumor regression was
observed for the combination in the sensitive model, however no
complete responses were observed.
Figure 6. The effect of BH-3 mimetic treatment, BRAF inhibition, and their combination on tumor growth in BRAF V600E mutant
xenografts. (A) A375 xenograft. (B) A2058 xenograft. PLX4720 was used as BRAF inhibitor and ABT-263 was used as BH3-mimetic. Both inhibitors
were given to mice PO daily at 100 mg/kg [45] for 12 days according to treatment group. Mice were euthanized when tumors reached maximal
allowed tumor volume. This occurred between days 9 and 12 for some but not all animals. Error bars represent standard error of the mean (SEM).
doi:10.1371/journal.pone.0101286.g006
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Our analysis of serial tumor biopsies in patients with BRAF-
mutant melanoma treated with BRAFi has revealed a number of
findings. First, in a panel of four anti-apoptotic BCL-2 family
members, only pretreatment levels of BCL-2 are associated with
outcome to BRAFi treatment; in particular, elevated BCL-2 levels
significantly correlated with a poorer outcome. Second, BRAFi
treatment results in significant increases in mRNA and protein
levels of the proapoptotic BH3-only proteins BIM and BID. Third,
BRAFi therapy drives a decrease in mRNA levels of MCL-1, but
an increase in the mRNA levels of BCL-XL and BCL-W; though
it is important to note that these mRNA changes did not translate
into significant changes in the level of protein expression of each of
these anti-apoptotic BCL-2 family members when using the RPPA
platform. Fourth, with the exception of pretreatment BCL-2 levels,
neither the pretreatment mRNA and protein levels of both pro-
and anti-apoptotic BCL-2 family members nor the magnitude of
change in these mRNA levels are associated with clinical outcome.
Finally, in vitro changes in mRNA expression of many anti- and
pro-apoptotic family members from several BRAF-mutant mela-
noma cell lines mirror the changes seen in samples obtained from
patients treated with BRAFi; thereby validating the use of these
cell lines to evaluate the efficacy of combinatorial strategies
targeting apoptosis.
These findings support the evaluation of the BH3-mimetic
navitoclax (ABT-263) and its tool compound, ABT-737, in
combination with BRAF inhibition as a strategy to improve the
effectiveness of BRAF inhibitors; as the targets of these agents, the
anti-apoptotic proteins BCL-2, BCL-XL, and BCL-W, either are
associated with outcome (BCL-2) to or increased in response
(BCL-XL and BCL-W) to BRAF inhibition [35,36]. Importantly,
the cell lines most resistant to the BH3-mimetics show overex-
pression of MCL-1, and pharmacologic downregulation of MCL-1
potentiates the lethality of ABT-737 in these cell lines [37,38]. As
MCL-1 expression is reduced and its binding partners BID and
BIM are increased with BRAFi treatment, it is predicted that
MCL-1 would be sufficiently abrogated by the changes of BRAF
inhibition. Providing further support of this strategy, preclinical
studies of ABT-737 in combination with a MEK inhibitor led to
enhanced lethality, in vitro and in vivo utilizing BRAF-mutant
melanoma cell lines and xenografts respectively, compared to
either agent alone [39]. Additionally, ABT-737 in combination
with the BRAF inhibitor PLX4720 showed augmentation of
apoptosis in BRAF mutant melanoma cell lines that was BIM
dependent and mediated through an enhancement of the
BIM:MCL-1 interaction [40]. We provide confirmation in vitro
that combining navitoclax with a BRAF inhibitor is clearly
synergistic with respect to inhibiting cell growth, and is associated
with a dramatic increase in apoptosis. Further, we show in vivo that
the combination is associated with deeper and more prolonged
regression compared with the single-agent BRAF inhibition and
single-agent navitoclax in both a BRAF inhibitor sensitive cell line
(A375) and a BRAF inhibitor resistant cell line (A2058).
Our clinical samples were obtained from patients who received
either single-agent vemurafenib or the combination of dabrafenib
and trametinib, yet are pooled together for this analysis. While
there is little difference in either the inhibition of the MAPK
pathway (pERK) or the changes in mediators of apoptosis in these
distinct patient subgroups at the biopsy time-point (10–14 days), it
is very possible that differences in single-agent BRAFi or
combination BRAFi and MEKi at that time-point may exist and
influence and therefore limit these findings. Additionally, we have
chosen not to focus on BCL2A1, a recently described melanoma
oncogene and mediator of BRAF inhibitor resistance in a subset of
melanomas, as this was the subject of an independent analysis in
our program [34]. This work cautions that a subset of patients
likely will not benefit from the combination of navitoclax with a
BRAF inhibitor regimen, though also opens the possibility that
BCL2A1 expression or change in expression may be a useful
biomarker to study in clinical trials of navitoclax in melanoma and
may become a biomarker used to exclude patients from future
clinical trials with navitoclax in melanoma. It should be noted that
obatoclax, another BH3-mimetic that targets BCL-2, BCL-XL,
and BCL-W but also MCL-1 and BCL2A1, has been shown to
enhance the activity of BRAF inhibitors in preclinical studies,
however human studies with obatoclax have been limited by the
CNS toxicity profile of this agent and there are currently no open
clinical trials studying obatoclax according to clinicaltrials.gov
[41–44].
For the first time, we demonstrate that BCL-2 expression is
inversely associated with patient outcome in the context of
targeted BRAFi therapy. Furthermore, we detail the changes in
expression of several key regulators of apoptosis in BRAF-mutant
melanoma in the setting of BRAF inhibition. We confirm the in
vitro synergy of BRAF inhibition with a BH-3 mimetic and
demonstrate improved outcome for this combination in vivo. All
these findings support the development of clinical trials evaluating
the role of adding agents that target apoptosis, generally, and
BH3-mimetics, specifically, in combination with BRAF-directed
therapy in patients with BRAF-mutant melanoma. The first of
these trials has recently opened (NCT01989585) and is a Cancer
Therapeutics Evaluation Program (CTEP)-sponsored study of
navitoclax in combination with the BRAF inhibitor dabrafenib
and the MEK inhibitor trametinib in BRAF-mutant melanoma.
Our data predict that we will see variability of response to this
combination, but that we will likely see an enhancement of anti-
tumor activity in most patients. The primary end-point of this trial
was designed taking this into consideration and seeks to compare
the magnitude of tumor regression of the triplet (navitoclax,
dabrafenib, and trametinib) versus the standard of care doublet
(dabrafenib and trametinib) in the randomized phase II portion of
the study. Further, emphasizing the need to empower trials with
tumor tissue analysis to permit predictive biomarker investigations,
this study also will compare baseline tumor characteristics and on-
treatment effects of treatment to determine potential biomarkers
that may predict outcome.
Supporting Information
Figure S1 Selected BCL-2 family member mRNA ex-
pression in samples from patients before treatment with
BRAF inhibition. Pre treatment expression of BCL2-L1, BCL2-
L2, BIM, BID and MCL-1 mRNA from tumors of patients with
metastatic melanoma does not correlate with response to BRAF
inhibition. (A–D,F) Linear regression between duration of patient
response to BRAF inhibition and mRNA expression levels relative
to endogenous gene bActin prior to treatment. (E) Excluding an
outlier from the linear regression shows a possible trend emerging
for BIM where higher levels of mRNA expression might be
positively associated with duration of treatment (p.0.05).
(EPS)
Figure S2 The effect of BRAF inhibition, BH3-mimetics
or their combination on apoptosis and protein expres-
sion levels of BCL2 family members in BRAF
V600E
melanoma cell lines. A. Fluorescence activated cell-sorting
(FACS) for Annexin after indicated drug treatment in BRAF
V600
cell lines A2058, SKMel28 and Mel526. Drug combinations used
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BRAF
V600 cell lines A2058, Mel526, UACC903 and UACC257
after 2, 6 and 24 hours treatment with a BRAFi, ABT and the
combination of both BRAFi and ABT.
(EPS)
Figure S3 BIM and Apptosis in Xenografts. IHC for BIM
in xenograft tumors from mice treated with vector, ABT, PLX or
the combination of ABT + PLX (A) and the detection of apoptosis
in these tumors using a TUNEL assay (B).
(TIFF)
Table S1 Patient Characteristics. Patients with metastatic
melanoma containing BRAF
V600E mutation (confirmed by
genotyping) were enrolled on clinical trials for treatment with a
BRAF inhibitor (vemurafenib) or combined BRAF + MEK
inhibitor (dabrafenib + trametinib). Listed are patient age, site of
disease, treatment, maximum response (RECIST), time to
progression (months) and BCL-2 mRNA levels.
(DOCX)
Table S2 PCR Primers. Primers used for RTPCR.
(DOCX)
Methods RPPA S1 Detailed methods for Reverse Phase
Protein Array analysis.
(DOCX)
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